XML 70 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Current Assets - Prepayments
12 Months Ended
Jun. 30, 2021
Current Prepayments [Abstract]  
Current Assets - Prepayments

Note 16. Current Assets - Prepayments

 

 

 

 

 

 

 

June 30, 2021

 

 

June 30, 2020

 

 

 

 

 

 

 

Restated

 

 

 

US$

 

 

US$

 

R&D Contract Research Organization

 

 

12,551,398

 

 

 

—

 

Insurance

 

 

1,820,059

 

 

 

320,521

 

Other prepayments

 

 

14,698

 

 

 

8,630

 

Total current prepayments

 

 

14,386,155

 

 

 

329,151

 

 

The R&D Contract Research Organization prepayment consists of prepayments on the Phase 3 clinical trial for OPT‑302 in order to secure sites across the world and start patient recruitment. These prepayments covered the initial startup of the Phase 3 clinical trials and are expected to be consumed within the next 12 months. The Insurance amount relates to specific Phase 3 Clinical trial insurance in place for various sites around the world covering periods to 2024. The non‑current portion of the prepayments are recorded as non‑current assets. Refer Note 19.